Earnings call transcript: Hologic's Q3 2025 shows stable growth

Hologic Inc. (HOLX) reported Q3 2025 revenue of $1.024 billion, a 0.4% increase, and non-GAAP EPS of $1.08, up 1.9%, both exceeding guidance despite headwinds in international markets like China and Africa. The company highlighted progress in its breast health segment, driven by the launch of Genius AI Detection PRO and strong performance from the Endomag acquisition, while also successfully mitigating tariff impacts by half to $10-$12 million quarterly. Hologic provided optimistic Q4 FY2025 guidance and projects mid-single-digit organic revenue growth for FY2026, signaling a return to accelerated growth through new product launches and strategic market expansion.

Analysis

Hologic (HOLX) reported Q3 2025 revenue of $1.024 billion (+0.4% YoY) and non-GAAP EPS of $1.08 (+1.9% YoY), both exceeding guidance. The company projects mid-single-digit organic revenue growth for FY2026, signaling an anticipated acceleration from current modest levels.

Key growth drivers include significant progress in breast health, marked by the launch of Genius AI Detection PRO and strong performance from the Endomag acquisition, contributing nearly $20 million. Molecular diagnostics also demonstrated resilience, growing 5.2% excluding COVID in the U.S., supported by key assay sales and Panther Fusion expansion.

Hologic faces headwinds from challenging international markets, particularly China and Africa, impacting diagnostics growth into early FY2026. The company mitigated tariff impacts by half to $10-$12 million quarterly, though this represents a nearly 100 basis point headwind to FY2026 gross margin.

Management is confident in returning to solid mid-single-digit organic growth, driven by new product innovations like Envision and continued accretive M&A. Strong cash flow and low net leverage provide financial flexibility for strategic expansion and shareholder returns.

Key Decisions for Investors

• Monitor Hologic's ability to achieve its projected mid-single-digit organic revenue growth in FY2026, particularly observing the performance of new product launches like Genius AI Detection PRO and the upcoming Envision system.
• Assess the impact of persistent international headwinds in China and Africa on the diagnostics segment, and evaluate the effectiveness of the company's strategies to mitigate these regional challenges.
• Consider the long-term margin implications of ongoing tariff expenses, despite successful mitigation efforts, and the potential for further operational efficiencies to offset these costs.
• Evaluate the company's capital allocation strategy, including continued share buybacks and patient M&A, for its contribution to shareholder value and strategic portfolio enhancement.